Anti-ERBB3/ Erbb-3/ ErbB-3 monoclonal antibody
Anti-ERBB3/ Erbb-3/ ErbB-3 antibody for FACS & in-vivo assay
Go to Erbb-3/ERBB3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T86350-Ab-1/ GM-Tg-hg-T86350-Ab-2 | Anti-Human Erbb-3/ERBB3 monoclonal antibody | Human |
GM-Tg-rg-T86350-Ab-1/ GM-Tg-rg-T86350-Ab-2 | Anti-Rat Erbb-3/ERBB3 monoclonal antibody | Rat |
GM-Tg-mg-T86350-Ab-1/ GM-Tg-mg-T86350-Ab-2 | Anti-Mouse Erbb-3/ERBB3 monoclonal antibody | Mouse |
GM-Tg-cynog-T86350-Ab-1/ GM-Tg-cynog-T86350-Ab-2 | Anti-Cynomolgus/ Rhesus macaque Erbb-3/ERBB3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T86350-Ab-1/ GM-Tg-felg-T86350-Ab-2 | Anti-Feline Erbb-3/ERBB3 monoclonal antibody | Feline |
GM-Tg-cang-T86350-Ab-1/ GM-Tg-cang-T86350-Ab-2 | Anti-Canine Erbb-3/ERBB3 monoclonal antibody | Canine |
GM-Tg-bovg-T86350-Ab-1/ GM-Tg-bovg-T86350-Ab-2 | Anti-Bovine Erbb-3/ERBB3 monoclonal antibody | Bovine |
GM-Tg-equg-T86350-Ab-1/ GM-Tg-equg-T86350-Ab-2 | Anti-Equine Erbb-3/ERBB3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T86350-Ab-1/ GM-Tg-hg-T86350-Ab-2; GM-Tg-rg-T86350-Ab-1/ GM-Tg-rg-T86350-Ab-2; GM-Tg-mg-T86350-Ab-1/ GM-Tg-mg-T86350-Ab-2; GM-Tg-cynog-T86350-Ab-1/ GM-Tg-cynog-T86350-Ab-2; GM-Tg-felg-T86350-Ab-1/ GM-Tg-felg-T86350-Ab-2; GM-Tg-cang-T86350-Ab-1/ GM-Tg-cang-T86350-Ab-2; GM-Tg-bovg-T86350-Ab-1/ GM-Tg-bovg-T86350-Ab-2; GM-Tg-equg-T86350-Ab-1/ GM-Tg-equg-T86350-Ab-2 |
Products Name | Anti-Erbb-3/ERBB3 monoclonal antibody |
Format | mab |
Target Name | Erbb-3 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-Erbb-3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T86350 |
Target Name | Erbb-3 |
Gene ID | 2065,13867,29496,711407,481105,101085388,785655,100059216 |
Gene Symbol and Synonyms | c-erbB-3,c-erbB3,ErbB-3,ERBB3,erbB3-S,Erbb3r,FERLK,HER3,LCCS2,MDA-BF-1,nuc-ErbB3,p180-ErbB3,p45-sErbB3,p85-sErbB3,VSCN1 |
Uniprot Accession | P21860,Q62799 |
Uniprot Entry Name | ERBB3_HUMAN,ERBB3_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target |
Disease | Non-Small Cell Lung Cancer, Prostate Cancer |
Gene Ensembl | ENSG00000065361 |
Target Classification | Checkpoint-Immuno Oncology, Kinase |
The target: Erbb-3, gene name: ERBB3, also named as ErbB-3, HER3, LCCS2, MDA-BF-1, c-erbB-3, c-erbB3, erbB3-S, p180-ErbB3, p45-sErbB3, p85-sErbB3. This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.